SILICON LABORATORIES INC. 10-Q

Item 1. Financial Statements Silicon Laboratories Inc. Condensed Consolidated Balance Sheets (In thousands, except per share data) (Unaudited) March 30, 2024 December 30, 2023 Assets Current assets: Cash and cash equivalents $ 191,489 $ 227,504 Short-term investments 141,201 211,720 Accounts receivable, net 32,616 29,295 Inventories 198,206 194,295 Prepaid expenses and other current assets 82,608 75,117 Total current assets 646,120 737,931 Property and equipment, net 142,155 145,890 Goodwill 376,389 376,389 Other intangible assets, net 53,453 59,533 Other assets, net 126,036 123,313 Total assets $ 1,344,153 $ 1,443,056 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 44,575 $ 57,498 Revolving line of credit — 45,000 Deferred revenue and returns liability 3,921 2,117 Other current liabilities 62,863 58,955 Total current liabilities 111,359 163,570 Other non-current liabilities 67,233 70,804 Total liabilities 178,592 234,374 Commitments and contingencies Stockholders’ equity: Preferred stock – $ 0.0001 par value; 10,000 shares authorized; no shares issued — — Common stock – $ 0.0001 par value; 250,000 shares authorized; 31,924 and 31,897 shares issued and outstanding at March 30, 2024 and December 30, 2023, respectively 3 3 Additional paid-in capital 29,830 16,973 Retained earnings 1,136,205 1,192,731 Accumulated other comprehensive loss ( 477 ) ( 1,025 ) Total stockholders’ equity 1,165,561 1,208,682 Total liabilities and stockholders’ equity $ 1,344,153 $ 1,443,056 The accompanying notes are an integral part of these Condensed Consolidated Financial Statements. 3 Table of Contents Silicon Laboratories Inc. Condensed Consolidated Statements of Operations (In thousands, except per share data) (Unaudited) Three Months Ended March 30, 2024 April 1, 2023 Revenues $ 106,375 $ 246,787 Cost of revenues 51,306 92,927 Gross profit 55,069 153,860 Operating expenses: Research and development 80,650 89,396 Selling, general and administrative 33,553 44,891 Operating expenses 114,203 134,287 Operating income (loss) ( 59,134 ) 19,573 Other income (expense): Interest income and other, net 2,732 4,836 Interest expense ( 509 ) ( 1,656 ) Income (loss) before income taxes ( 56,911 ) 22,753 Provision (benefit) for income taxes ( 385 ) 7,753 Equity-method loss — ( 1,033 ) Net income (loss) $ ( 56,526 ) $ 13,967 Earnings (loss) per share: Basic $ ( 1.77 ) $ 0.44 Diluted $ ( 1.77 ) $ 0.41 Weighted-average common shares outstanding: Basic 31,910 31,959 Diluted 31,910 33,753 The accompanying notes are an integral part of these Condensed Consolidated Financial Statements. 4 Table of Contents Silicon Laboratories Inc. Condensed Consolidated Statements of Comprehensive Income (In thousands) (Unaudited) Three Months Ended March 30, 2024 April 1, 2023 Net income (loss) $ ( 56,526 ) $ 13,967 Other comprehensive income, before tax: Net changes to available-for-sale securities: Unrealized gains arising during the period 624 2,997 Reclassification for losses included in net income (loss) 15 2,614 Net changes to cash flow hedges: Unrealized gains arising during the period 275 38 Reclassification for gains included in net income (loss) ( 234 ) ( 30 ) Other comprehensive income, before tax 679 5,619 Provision for income taxes 131 1,394 Other comprehensive income 548 4,225 Comprehensive income (loss) $ ( 55,978 ) $ 18,192 The accompanying notes are an integral part of these Condensed Consolidated Financial Statements. 5 Table of Contents Silicon Laboratories Inc. Condensed Consolidated Statements of Changes in Stockholders’ Equity (In thousands) (Unaudited) Three Months Ended March 30, 2024 Shares Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive Income (Loss) Total Stockholders’ Equity Balance as of December 30, 2023 31,897 $ 3 $ 16,973 $ 1,192,731 $ ( 1,025 ) $ 1,208,682 Net loss — — — ( 56,526 ) — ( 56,526 ) Other comprehensive income — — — — 548 548 Stock issuances, net of shares withheld for taxes 27 — ( 707 ) — — ( 707 ) Repurchases of common stock — — — — — — Stock-based compensation — — 13,564 — — 13,564 Balance as of March 30, 2024 31,924 $ 3 $ 29,830 $ 1,136,205 $ ( 477 ) $ 1,165,561 Three Months Ended April 1, 2023 Shares Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive Income (Loss) Total Stockholders’ Equity Balance as of December 31, 2022 31,994 $ 3 $ — $ 1,415,693 $ ( 10,688 ) $ 1,405,008 Net income — — — 13,967 — 13,967 Other comprehensive income — — — — 4,225 4,225 Stock issuances, net of shares withheld for taxes 98 — ( 6,931 ) — — ( 6,931 ) Repurchases of common stock ( 95 ) — ( 9,732 ) ( 3,746 ) — ( 13,478 ) Stock-based compensation — — 16,663 — — 16,663 Balance as of April 1, 2023 31,997 $ 3 $ — $ 1,425,914 $ ( 6,463 ) $ 1,419,454 The accompanying notes are an integral part of these Condensed Consolidated Financial Statements. 6 Table of Contents Silicon Laboratories Inc. Condensed Consolidated Statements of Cash Flows (In thousands) (Unaudited) Three Months Ended March 30, 2024 April 1, 2023 Operating Activities Net income (loss) $ ( 56,526 ) $ 13,967 Adjustments to reconcile net income to net cash used in operating activities: Depreciation of property and equipment 6,634 6,235 Amortization of other intangible assets 6,079 6,510 Amortization of debt issuance costs — 523 Stock-based compensation expense 13,612 16,638 Equity-method loss — 1,033 Deferred income taxes ( 5,270 ) ( 2,670 ) Changes in operating assets and liabilities: Accounts receivable ( 3,321 ) ( 16,257 ) Inventories ( 3,958 ) ( 32,794 ) Prepaid expenses and other assets ( 15,466 ) 11,530 Accounts payable ( 13,829 ) ( 12,966 ) Other current liabilities and income taxes 1,554 ( 8,529 ) Deferred revenue and returns liability 1,804 4,478 Other non-current liabilities ( 3,113 ) ( 978 ) Net cash used in operating activities ( 71,800 ) ( 13,280 ) Investing Activities Purchases of marketable securities ( 9,794 ) ( 66,113 ) Sales of marketable securities 25,763 170,317 Maturities of marketable securities 55,188 157,734 Purchases of property and equipment ( 2,047 ) ( 7,657 ) Proceeds from sale of equity investment 12,382 — Net cash provided by investing activities 81,492 254,281 Financing Activities Payments on debt ( 45,000 ) — Repurchases of common stock — ( 17,608 ) Payment of taxes withheld for vested stock awards ( 1,048 ) ( 6,931 ) Proceeds from the issuance of common stock 341 — Net cash used in financing activities ( 45,707 ) ( 24,539 ) Increase (decrease) in cash and cash equivalents ( 36,015 ) 216,462 Cash and cash equivalents at beginning of period 227,504 499,915 Cash and cash equivalents at end of period $ 191,489 $ 716,377 The accompanying notes are an integral part of these Condensed Consolidated Financial Statements. 7 Table of Contents Silicon Laboratories Inc. Notes to Condensed Consolidated Financial Statements (Unaudited) 1. Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The information included herein contains all normal recurring accruals and adjustments which, in the opinion of management, are necessary to present fairly Silicon Laboratories Inc.’s (the “Company”) financial position, results of its operations, comprehensive income, stockholders’ equity, and cash flows. The Condensed Consolidated Balance Sheet as of December 30, 2023 was derived from the Company’s audited Consolidated Financial Statements. All intercompany balances and transactions have been eliminated in consolidation. The condensed consolidated results of operations for the three months ended March 30, 2024 are not necessarily indicative of the results to be expected for the full year. These Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and notes thereto for the year ended December 30, 2023, included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 20, 2024. The Company prepares financial statements on a 52- or 53-week fiscal year that ends on the Saturday closest to December 30. Fiscal 2024 will have 52 weeks and fiscal 2023 had 52 weeks. In a 52-week year, each fiscal quarter consists of 13 weeks. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Among the significant estimates affecting the financial statements are those related to inventories, goodwill, acquired intangible assets, other long-lived assets, revenue recognition, stock-based compensation, and income taxes. Actual results could differ from those estimates, and such differences could be material to the financial statements. The Company periodically reviews the assumptions used in its financial statement estimates. Recent Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280)—Improvements to Reportable Segment Disclosures . This ASU requires interim and annual disclosure of significant segment expenses that are regularly provided to the chief operating decision-maker (“CODM”) and included within the reported measure of a segment’s profit or loss, requires interim disclosures about a reportable segment’s profit or loss and assets that are currently required annually, requires disclosure of the position and title of the CODM, clarifies circumstances in which an entity can disclose multiple segment measures of profit or loss, and contains other disclosure requirements. This authoritative guidance is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effect of this new guidance on our consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740)—Improvements to Income Tax Disclosures . This ASU requires that reporting entities disclose specific categories in the effective tax rate reconciliation as well as information about income taxes paid. The authoritative guidance is effective for annual periods beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effect of this new guidance on our consolidated financial statements. 8 Table of Contents Silicon Laboratories Inc. Notes to Condensed Consolidated Financial Statements (Continued) (Unaudited) 2. Earnings Per Share The following table sets forth the computation of basic and diluted earnings per share (in thousands, except per share data): Three Months Ended March 30, 2024 April 1, 2023 Net income (loss) $ ( 56,526 ) $ 13,967 Shares used in computing basic earnings per share 31,910 31,959 Effect of dilutive securities: Convertible debt and stock-based awards — 1,794 Shares used in computing diluted earnings per share 31,910 33,753 Earnings (loss) per share: Basic $ ( 1.77 ) $ 0.44 Diluted $ ( 1.77 ) $ 0.41 Diluted shares for the three months ended March 30, 2024 excluded 0.4 million shares due to the Company's net loss for the period. For the three months ended April 1, 2023, approximately 1.2 million shares were included in the denominator for the calculation of diluted earnings per share (related to the not yet converted or redeemed 2025 Notes.) Securities that were anti-dilutive were insignificant and were excluded from the computation of diluted earnings per share for the three months ended April 1, 2023. 3. Fair Value of Financial Instruments The fair values of the Company’s financial instruments are recorded using a hierarchical disclosure framework based upon the level of subjectivity of the inputs used in measuring assets and liabilities. The three levels are described below: Level 1 - Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 - Inputs other than Level 1 that are directly or indirectly observable, such as quoted prices for similar assets or liabilities and quoted prices in less active markets. Level 3 - Inputs are unobservable for the asset or liability and are developed based on the best information available in the circumstances, which might include the Company’s own data. 9 Table of Contents Silicon Laboratories Inc. Notes to Condensed Consolidated Financial Statements (Continued) (Unaudited) 3. Fair Value of Financial Instruments (Continued) The following summarizes the valuation of the Company’s financial instruments (in thousands). The tables do not include either cash on hand or assets and liabilities that are measured at historical cost or any basis other than fair value. Fair Value Measurements at March 30, 2024 Using Description Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Total Cash equivalents: Money market funds $ 107,746 $ — $ 107,746 Total cash equivalents $ 107,746 $ — $ 107,746 Short-term investments: Corporate debt securities $ — $ 58,743 $ 58,743 Government debt securities — 82,458 82,458 Total short-term investments $ — $ 141,201 $ 141,201 Total $ 107,746 $ 141,201 $ 248,947 Fair Value Measurements at December 30, 2023 Using Description Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Total Cash equivalents: Money market funds $ 137,195 $ — $ 137,195 Total cash equivalents $ 137,195 $ — $ 137,195 Short-term investments: Corporate debt securities $ — $ 130,047 $ 130,047 Government debt securities — 81,673 81,673 Total short-term investments $ — $ 211,720 $ 211,720 Total $ 137,195 $ 211,720 $ 348,915 Valuation methodology The Company’s cash equivalents and short-term investments that are classified as Level 2 are valued using non-binding market consensus prices that are corroborated with observable market data; quoted market prices for similar instruments in active markets; quoted prices in less active markets; or pricing models, such as a discounted cash flow model, with all significant inputs derived from or corroborated with observable market data. The Company’s foreign currency derivative instruments are valued using discounted cash flow models. The assumptions used in preparing the valuation models include foreign exchange rates, forward and spot prices for currencies and market observable data of similar instruments. 10 Table of Contents Silicon Laboratories Inc. Notes to Condensed Consolidated Financial Statements (Continued) (Unaudited) 3. Fair Value of Financial Instruments (Continued) The following summarizes the components of available-for-sale investments: Reported As As of March 30, 2024 Amortized Cost Basis Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash Equivalent Marketable Securities Corporate debt securities $ 59,107 $ 46 $ ( 410 ) $ 58,743 $ — $ 58,743 Government debt securities 82,685 19 ( 246 ) 82,458 — 82,458 Money market funds 107,746 — — 107,746 107,746 — Total $ 249,538 $ 65 $ ( 656 ) $ 248,947 $ 107,746 $ 141,201 Reported As As of December 30, 2023 Amortized Cost Basis Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash Equivalent Marketable Securities Corporate debt securities $ 130,858 $ 69 $ ( 880 ) $ 130,047 $ — $ 130,047 Government debt securities 82,091 137 ( 555 ) 81,673 — 81,673 Money market funds 137,195 — — 137,195 137,195 — Total $ 350,144 $ 206 $ ( 1,435 ) $ 348,915 $ 137,195 $ 211,720 Contractual maturities of investments The Company’s available-for-sale investments are reported at fair value, with unrealized gains and losses, net of tax, recorded as a component of accumulated other comprehensive loss in the Condensed Consolidated Balance Sheet. The following summarizes the contractual underlying maturities of the Company’s available-for-sale investments at March 30, 2024 (in thousands): Cost Fair Value Due in one year or less $ 112,498 $ 112,010 Due after one year through five years 29,294 29,191 $ 141,792 $ 141,201 Unrealized Gains and Losses The available-for-sale investments that were in a continuous unrealized loss position, aggregated by length of time that individual securities have been in a continuous loss position, were as follows (in thousands): Less Than 12 Months 12 Months or Greater Total As of March 30, 2024 Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Corporate debt securities $ 2,501 $ ( 1 ) $ 30,323 $ ( 410 ) $ 32,824 $ ( 411 ) Government debt securities 36,642 ( 166 ) 30,174 ( 79 ) 66,816 ( 245 ) $ 39,143 $ ( 167 ) $ 60,497 $ ( 489 ) $ 99,640 $ ( 656 ) 11 Table of Contents Silicon Laboratories Inc. Notes to Condensed Consolidated Financial Statements (Continued) (Unaudited) 3. Fair Value of Financial Instruments (Continued) Less Than 12 Months 12 Months or Greater Total As of December 30, 2023 Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Corporate debt securities $ 12,449 $ ( 13 ) $ 95,760 $ ( 867 ) $ 108,209 $ ( 880 ) Government debt securities 28,255 ( 115 ) 31,122 ( 440 ) 59,377 ( 555 ) $ 40,704 $ ( 128 ) $ 126,882 $ ( 1,307 ) $ 167,586 $ ( 1,435 ) The gross unrealized losses as of March 30, 2024 and December 30, 2023 were due primarily to changes in market interest rates. At March 30, 2024 and December 30, 2023, there were no material unrealized gains associated with the Company’s available-for-sale investments. The Company records an allowance for credit loss when a decline in investment market value is due to credit-related factors. When evaluating an investment for impairment, the Company reviews factors such as the severity of the impairment, changes in underlying credit ratings, forecasted recovery, the Company’s intent to sell or the likelihood that it would be required to sell the investment before its anticipated recovery in market value and the probability that the scheduled cash payments will continue to be made. As of March 30, 2024, there were no material declines in the market value of available-for-sale investments due to credit-related factors. Fair values of other financial instruments The Company’s other financial instruments, including cash, accounts receivable and accounts payable, are recorded at amounts that approximate their fair values due to their short maturities. 4. Derivative Financial Instruments The Company uses derivative financial instruments to manage certain exposures to the variability of foreign currency exchange rates. The Company’s objective is to offset increases and decreases in expenses resulting from these exposures with gains and losses on the derivative contracts, thereby reducing volatility of earnings. The Company does not use derivative contracts for speculative or trading purposes. The Company recognizes derivatives, on a gross basis, in the Condensed Consolidated Balance Sheet at fair value. Cash flows from derivatives are classified according to the nature of the cash receipt or payment in the Condensed Consolidated Statement of Cash Flows. Cash Flow Hedges Foreign Currency Forward Contracts The Company uses foreign currency forward contracts to reduce the earnings impact that exchange rate fluctuations have on operating expenses denominated in currencies other than the U.S. dollar. Changes in the fair value of the contracts are recorded in accumulated other comprehensive loss in the Condensed Consolidated Balance Sheet and subsequently reclassified into earnings in the period during which the hedged transaction is recognized. The reclassified amount is reported in the same financial statement line item as the hedged item. If the foreign currency forward contracts are terminated or can no longer qualify as hedging instruments prior to maturity, the fair value of the contracts recorded in accumulated other comprehensive loss may be recognized in the Condensed Consolidated Statement of Operations based on an assessment of the contracts at the time of termination. As of March 30, 2024, the company held no such foreign currency forward contracts. The fair value of the contracts, contract gains or losses recognized in other comprehensive income and amounts reclassified from accumulated other comprehensive loss into earnings were not material for any of the periods presented. 12 Table of Contents Silicon Laboratories Inc. Notes to Condensed Consolidated Financial Statements (Continued) (Unaudited) 5. Supplemental Information The following table shows the details of selected Condensed Consolidated Balance Sheet items (in thousands): Inventories March 30, 2024 December 30, 2023 Work in progress $ 173,379 $ 173,802 Finished goods 24,827 20,493 $ 198,206 $ 194,295 Lease income The Company leases a portion of its headquarter facilities to other tenants. Lease income from operating leases was $ 0.8 million and $ 0.7 million during the three months ended March 30, 2024 and April 1, 2023, respectively. 6. Debt Credit Facility The Company and certain of its domestic subsidiaries (the “Guarantors”) have a $ 400 million revolving credit facility, as amended on June 30, 2023, with a maturity date of June 30, 2028. The credit facility includes a $ 25 million letter of credit sublimit and a $ 10 million swingline loan sublimit. The Company also has an option to increase the size of the borrowing capacity by up to the greater of an aggregate of $ 250 million and 100 % of EBITDA of the last four fiscal quarters, plus an amount that would not cause a secured net leverage ratio (funded debt secured by assets/EBITDA) to exceed 3.50 to 1.00, subject to certain conditions. The credit facility, other than swingline loans, will bear interest at the Adjusted Term Secured Overnight Financing Rate (“SOFR”) plus an applicable margin or, at the option of the Company, a base rate (defined as the highest of the Wells Fargo prime rate, the Federal Funds rate plus 0.50 % and the Adjusted Term SOFR plus 1.00 %) plus an applicable margin. Swingline loans accrue interest at the base rate plus the applicable margin for base rate loans. The applicable margins for the Adjusted Term SOFR loans range from 1.00 % to 1.75 % and for base rate loans range from 0.00 % to 0.75 %, depending in each case, on the leverage ratio as defined in the credit facility. The credit facility contains various conditions, covenants and representations with which the Company must be in compliance in order to borrow funds and to avoid an event of default, including financial covenants that the Company must maintain a consolidated net leverage ratio (funded indebtedness less cash and cash equivalents up to $ 750 million and divided by EBITDA) of no more than 4.25 to 1, and a minimum interest coverage ratio (EBITDA/interest payments) of no less than 2.50 to 1. As of March 30, 2024, the Company was in compliance with all covenants of the credit facility. The Company’s obligations under the credit facility are guaranteed by the Guarantors and are secured by a security interest in substantially all assets of the Company and the Guarantors. As of March 30, 2024, no amounts were outstanding on the credit facility. 7. Commitments and Contingencies Litigation The Company is involved in various legal proceedings that have arisen in the normal course of business. While the ultimate results cannot be predicted with certainty, the Company does not expect them to have a material adverse effect on its Condensed Consolidated Financial Statements. 13 Table of Contents Silicon Laboratories Inc. Notes to Condensed Consolidated Financial Statements (Continued) (Unaudited) 8. Revenues The Company groups its products as Industrial & Commercial or Home & Life based on the target markets they address. The following represents revenue by product category (in thousands): Three Months Ended March 30, 2024 April 1, 2023 Industrial & Commercial $ 65,262 $ 150,713 Home & Life 41,113 96,074 $ 106,375 $ 246,787 A portion of the Company’s sales are made to distributors under agreements allowing certain rights of return and/or price protection related to the final selling price to the end customers. These factors impact the timing and uncertainty of revenues and cash flows. During the three months ended March 30, 2024 and April 1, 2023, the Company recognized revenue of $ 4.2 million and $ 4.9 million, respectively, from performance obligations that were satisfied in previous reporting periods. The following disaggregates the Company’s revenue by sales channel (in thousands): Three Months Ended March 30, 2024 April 1, 2023 Distributors $ 70,360 $ 204,872 Direct customers 36,015 41,915 $ 106,375 $ 246,787 9. Stock-Based Compensation Stock-based compensation costs are based on the fair values on the date of grant for stock awards and stock options and on the date of enrollment for the employee stock purchase plans. The fair values of stock awards (such as restricted stock units (“RSUs”), performance stock units (“PSUs”) and restricted stock awards (“RSAs”)) are estimated based on their intrinsic values. The fair values of market stock awards (“MSUs”) are estimated using a Monte Carlo simulation. The fair values of stock options and employee stock purchase plans are estimated using the Black-Scholes option-pricing model. The following table presents details of stock-based compensation costs recognized in the Condensed Consolidated Statements of Operations (in thousands): Three Months Ended March 30, 2024 April 1, 2023 Cost of revenues $ 412 $ 298 Research and development 9,722 9,491 Selling, general and administrative 3,478 6,849 13,612 16,638 Income tax provision 1,727 1,786 Total $ 11,885 $ 14,852 The Company had approximately $ 80.3 million of total unrecognized compensation cost related to equity grants as of March 30, 2024 that is expected to be recognized over a weighted-average period of approximately 2.0 years. 14 Table of Contents Silicon Laboratories Inc. Notes to Condensed Consolidated Financial Statements (Continued) (Unaudited) 10. Income Taxes Provision for income taxes includes both domestic and foreign income taxes at the applicable tax rates adjusted for non-deductible expenses, research and development tax credits, global intangible low-taxed income, Subpart F income inclusions, and other permanent differences. Income tax benefit was $ 0.4 million and expense was $ 7.8 million for the three months ended March 30, 2024 and April 1, 2023, resulting in effective tax rates of 0.7 % and 35.7 %, respectively. The decrease in the provision for income taxes for the three months ended March 30, 2024 is primarily due to reporting a tax benefit on pre-tax book loss for the current period compared to tax expense on pre-tax book income for the three months ended April 1, 2023. Uncertain Tax Positions As of March 30, 2024, the Company had gross unrecognized tax benefits, inclusive of interest, of $ 5.9 million, of which $ 5.3 million would affect the effective tax rate if recognized. During the three months ended March 30, 2024, the Company did not release any unrecognized tax benefits. The Company recognizes interest and penalties related to unrecognized tax benefits in the provision for income taxes. These amounts were not material for any of the periods presented. Following the completion of the Norwegian Tax Administration (“NTA”) examination of the Company’s Norwegian subsidiary for income tax matters relating to fiscal years 2013 - 2016, the Company received an assessment from the NTA in December 2017 concerning an adjustment to its 2013 taxable income related to the pricing of an intercompany transaction. The Company is currently appealing the assessment. The adjustment to the pricing of the intercompany transaction results in approximately 141.3 million Norwegian kroner, or $ 13.0 million, additional Norwegian income tax. The Company disagrees with the NTA’s assessment and believes the Company’s position on this matter is more likely than not to be sustained. The Company plans to exhaust all available administrative remedies. If unable to resolve this matter through administrative remedies with the NTA, the Company plans to pursue judicial remedies. The Company believes that it has accrued adequate reserves related to all matters contained in tax periods open to examination. Should the Company experience an unfavorable outcome in the NTA matter, however, such an outcome could have a material impact on its financial statements. Tax years 2015 through 2024 remain open to examination by the major taxing jurisdictions in which the Company operates. The Company’s 2021 tax year is currently under examination in India. Although the outcome of tax audits is always uncertain, the Company believes that the results of the examination will not materially impact its financial position or results of operations. The Company is not currently under audit in any other major taxing jurisdiction. The Company believes it is reasonably possible that its gross unrecognized tax benefits will decrease by approximately $ 1.9 million, inclusive of interest, in the next 12 months due to the lapse of the statute of limitations. 11. Restructuring Activities During the fourth quarter of 2023, the Company implemented a workforce reduction of approximately 10 % of its employees to reduce costs and align its business in response to market conditions. The following table summarizes the activity of the restructuring liability during the periods presented (in millions): Three Months Ended March 30, 2024 Balance, beginning of period $ 4.4 Charges 0.5 Payments 1.0 Balance, end of period $ 3.9 15 Table of Contents Silicon Laboratories Inc. Notes to Condensed Consolidated Financial Statements (Continued) (Unaudited) 11. Restructuring Activities (Continued) During the three months ended March 30, 2024, restructuring charges of $ 0.5 million were recognized in operating expenses in the Condensed Consolidated Statements of Operations. 16 Table of Contents